Business
Talphera Announces Fourth Quarter 2023 Financial Results and Provides Corporate Update
Company rebranding and corporate transformation to Talphera completed in Q1 2024 First patient enrollment in the NEPHRO CRRT registrational study expected in
About this update from Talphera, Inc.
[{"type":"text","content":"Company rebranding and corporate transformation to Talphera completed in Q1 2024 \nFirst patient enrollment in the NEPHRO CRRT registrational study expected in Q1 2024 with a projected PMA submission by the end of 2024\nCash and investments at December 31, 2023 of $9.4 million together with the royalty and equity financings completed in January 2024 expected to provide cash runway to a potential Niyad™ approval in Q2 2025\nConference call and webcast to be held Wednesday, March 6, 2024 at 4:30 pm ET \nSAN MATEO, Calif., March 6, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), (\"Talphera\"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced fourth quarter 2023 financial results and provided a corporate update.\n\"We are excited about our company transformation to Talphera earlier this year. With the divestment of DSUVIA last year and priority focus on our new lead asset, Niyad, we expect a series of significant upcoming milestones. This transformation has generated new interest and investments in Talphera, which has provided us with the capital and commitments projected to support the development of Niyad through a potential FDA approval by the middle of next year,\" commented Vince Angotti, Chief Executive Officer of Talphera. \"With three decades of nafamostat use in Japan and South Korea, we are looking forward to having the first patient enrolled in the NEPHRO CRRT registrational study, which is expected in the coming weeks. Our priority this year is the successful completion of this trial and the submission of a PMA to the FDA by the end of 2024,\" Angotti continued.\nFourth quarter 2023 and recent highlights\nIn January of this year, the Company announced a corporate rebranding, changing its name from AcelRx Pharmaceuticals, Inc. to Talphera, Inc. (\"Talphera\"). The decision to rebrand was made following the divestment of assets indicated for acute pain and the shift in focus to its new lead asset, Niyad, reinforcing the Company's vision of developing and commercializing products to support healthcare providers in optimizing outcomes in medically supervised settings. Talphera began trading on the Nasdaq Global Market under the ticker symbol \"TLPH\" on January 10, 2024.In January 2024, Talphera announced...